ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates

Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 months Safety profile consistent with prior studies and comparable to kidney biopsy Resumed manufacturing and both PROACT 1 and PROACT 2 Phase 3 trials Management to host live webcast today at 8:00 a.m. ET REGEN-007 Phase 2 Trial Interim Efficacy & Safety Data In Group 1, as of May 7, 2024, patients with at least 12 months follow-up after the second injection of rilparencel (n=13) show stabilized kidney function for 18 m ...